ScreenerHero

OMER Omeros Corporation

NAS · US · Healthcare · Biotechnology · omeros.com
18.75USD+1.30%Mkt Cap: 1.36B $P/E: 15.37

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead p…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap1.36B USD
Enterprise Value1.50B USD
Revenue (TTM)38.42M USD
Gross Profit14.73M USD
Net Income (TTM)-3.35M USD
Revenue/Share0.55 USD
Last Price18.75 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees175
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)15.37
P/E (Forward)15.05
PEG0.81
EV/EBITDA-20.93
EV/Revenue39.17
P/S34.87
P/B-26.00
EPS (TTM)1.20
EPS (Forward)1.23
52W Range
4.06086% of range21.24
52W High21.24 USD
52W Low4.060 USD
Profitability
Gross Margin38.34%
Oper. Margin0.26%
EBITDA Margin-187.17%
Profit Margin324.88%
ROE2.76%
ROA-1.03%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-116.09M USD
CapEx (TTM)65.00K USD
FCF Margin477.10%
FCF Yield13.51%
Net Debt164.92M USD
Net Debt/EBITDA-2.29
Balance Sheet
Debt/Equity-1.97
Current Ratio1.95
Quick Ratio1.61
Book Value/Sh-0.71 USD
Cash/Share1.82 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.7 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)27.50 USD
Upside (mean)+46.7%
Target Range22.00 USD – 33.00 USD
22.00+46.7% to mean33.00
# Analysts2
Ownership
Shares Out.72.39M
Float69.29M
Insiders4.08%
Institutions51.41%
Short Interest
Short Ratio7.9d
Short % Float17.89%
Short % Out.17.26%
Shares Short12.49M
Short (prev mo.)14.64M
Technical
SMA 5017.26 (+8.6%)
SMA 20013.09 (+43.2%)
Beta2.57
S&P 52W Chg16.45%
Avg Vol (30d)1.57M
Avg Vol (10d)1.07M
Technical Indicators
RSI (14)54.4
MACD0.6203
MACD Signal0.9374
MACD Hist.-0.3170
BB Upper20.94 USD
BB Middle19.00 USD
BB Lower17.06 USD
BB Width20.45%
ATR (14)0.8515 USD
Vol Ratio (20d)0.46x